|
1
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cheung A, Shah S, Parker J, Soor P, Limbu
A, Sheriff M and Boussios S: Non-epithelial ovarian cancers: How
much do we really know? Int J Environ Res Public Health.
19(1106)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Howlader N, Noone AM, Krapcho M, Miller D,
Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR (eds), et
al: SEER cancer statistics review, 1975-2017, National Cancer
Institute. Bethesda, MD, 2020. https://seer.cancer.gov/csr/1975_2017.
|
|
4
|
Landrum LM, Java J, Mathews CA, Lanneau GS
Jr, Copeland LJ, Armstrong DK and Walker JL: Prognostic factors for
stage III epithelial ovarian cancer treated with intraperitoneal
chemotherapy: A gynecologic oncology group study. Gynecol Oncol.
130:12–18. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Boussios S, Rassy E, Moschetta M, Ghose A,
Adeleke S, Sanchez E, Sheriff M, Chargari C and Pavlidis N: BRCA
mutations in ovarian and prostate cancer: Bench to bedside. Cancers
(Basel). 14(3888)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Trimble EL, Christan MC and Korsay C:
Surgical debulking plus paclitaxel-based adjuvant chemotherapy
superior to previous ovarian cancer therapies. Oncology.
13(1068)1999.
|
|
7
|
Pavlidis N, Rassy E, Vermorken JB, Assi T,
Kattan J, Boussios S and Smith-Gagen J: The outcome of patients
with serous papillary peritoneal cancer, fallopian tube cancer, and
epithelial ovarian cancer by treatment eras: 27 Years data from the
SEER registry. Cancer Epidemiol. 75(102045)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
del Carmen MG, Birrer M and Schorge JO:
Clear cell carcinoma of the ovary: A review of the literature.
Gynecol Oncol. 126:481–490. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ,
Soletormos G, Torre GC, Tuxen MK and Zwirner M: CA125 in ovarian
cancer: European group on tumor markers guidelines for clinical
use. Int J Gynecol Cancer. 15:679–691. 2005.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tian C, Markman M, Zaino R, Ozols RF,
McGuire WP, Muggia FM, Rose PG, Spriggs D and Armstrong DK: CA-125
change after chemotherapy in prediction of treatment outcome among
advanced mucinous and clear cell epithelial ovarian cancers: A
gynecologic oncology group study. Cancer. 115:1395–1403.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ghose A, Bolina A, Mahajan I, Raza SA,
Clarke M, Pal A, Sanchez E, Rallis KS and Boussios S: Hereditary
ovarian cancer: Towards a cost-effective prevention strategy. Int J
Environ Res Public Health. 19(12057)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kim VN, Han J and Siomi MC: Biogenesis of
small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Kosaka N, Yoshioka Y, Fujita Y and Ochiya
T: Versatile roles of extracellular vesicles in cancer. J Clin
Invest. 126:1163–1172. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Kim VN: MicroRNA biogenesis: Coordinated
cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385.
2005.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Pritchard CC, Cheng HH and Tewari M:
MicroRNA profiling: approaches and considerations. Nat Rev Genet.
13:358–369. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Cortez MA, Bueso-Ramos C, Ferdin J,
Lopez-Berestein G, Sood AK and Calin GA: MicroRNAs in body
fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol.
8:467–477. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nagamitsu Y, Nishi H, Sasaki T, Takaesu Y,
Terauchi F and Isaka K: Profiling analysis of circulating microRNA
expression in cervical cancer. Mol Clin Oncol. 5:189–194.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka
Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda
T, et al: Integrated extracellular microRNA profiling for ovarian
cancer screening. Nat Commun. 9(4319)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gurung A, Hung T, Morin J and Gilks CB:
Molecular abnormalities in ovarian carcinoma: Clinical,
morphological and therapeutic correlates. Histopathology. 62:59–70.
2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Grandi G, Toss A, Cortesi L, Botticelli L,
Volpe A and Cagnacci A: The association between endometriomas and
ovarian cancer: Preventive effect of inhibiting ovulation and
menstruation during reproductive life. Biomed Res Int.
2015(751571)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Schrauder MG, Strick R, Schulz-Wendtland
R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A,
Hein A, et al: Circulating micro-RNAs as potential blood-based
markers for early stage breast cancer detection. PLoS One.
7(e29770)2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ohyashiki K, Umezu T, Yoshizawa SI, Ito Y,
Ohyashiki M, Kawashima H, Tanaka M, Kuroda M and Ohyashiki JH:
Clinical impact of down-regulated plasma miR-92a levels in
non-Hodgkin's lymphoma. PLoS One. 6(e16408)2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Huang HY, Lin YC, Li J, Huang KY, Shrestha
S, Hong HC, Tang Y, Chen YG, Jin CN, Yu Y, et al: miRTarBase 2020:
Updates to the experimentally validated microRNA-target interaction
database. Nucleic Acids Res. 48 (D1):D148–D154. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shah S, Cheung A, Kutka M, Sheriff M and
Boussios S: Epithelial ovarian cancer: Providing evidence of
predisposition genes. Int J Environ Res Public Health.
19(8113)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ghose A, Gullapalli SVN, Chohan N, Bolina
A, Moschetta M, Rassy E and Boussios S: Applications of proteomics
in ovarian cancer: Dawn of a new era. Proteomes.
10(16)2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Taniguchi F: New knowledge and insights
about the malignant transformation of endometriosis. J Obstet
Gynaecol Res. 43:1093–1100. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hua M, Qin Y, Sheng M, Cui X, Chen W,
Zhong J, Yan J and Chen Y: miR-145 suppresses ovarian cancer
progression via modulation of cell growth and invasion by targeting
CCND2 and E2F3. Mol Med Rep. 19:3575–3583. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kato JY and Sherr CJ: Inhibition of
granulocyte differentiation by G1 cyclins D2 and D3 but not D1.
Proc Natl Acad Sci USA. 90:11513–11517. 1993.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Song H, Hogdall E, Ramus SJ, Dicioccio RA,
Hogdall C, Quaye L, McGuire V, Whittemore AS, Shah M, Greenberg D,
et al: Effects of common germ-line genetic variation in cell cycle
genes on ovarian cancer survival. Clin Cancer Res. 14:1090–1095.
2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhu H, Dougherty U, Robinson V, Mustafi R,
Pekow J, Kupfer S, Li YC, Hart J, Goss K, Fichera A, et al: EGFR
signals downregulate tumor suppressors miR-143 and miR-145 in
Western diet-promoted murine colon cancer: Role of G1 regulators.
Mol Cancer Res. 9:960–975. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chang L, Guo R, Yuan Z, Shi H and Zhang D:
LncRNA HOTAIR regulates CCND1 and CCND2 expression by sponging
miR-206 in ovarian cancer. Cell Physiol Biochem. 49:1289–1303.
2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lu S, Liu W, Shi H and Zhou H: Exosomal
miR-34b inhibits proliferation and the epithelial-mesenchymal
transition by targeting Notch2 in ovarian cancer. Oncol Lett.
20:2721–2728. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Revythis A, Limbu A, Mikropoulos C, Ghose
A, Sanchez E, Sheriff M and Boussios S: Recent insights into PARP
and immuno-checkpoint inhibitors in epithelial ovarian cancer. Int
J Environ Res Public Health. 19(8577)2022.PubMed/NCBI View Article : Google Scholar
|
